Important safety informationRespiral is not a reliever medication. It must not be used to treat acute bronchospasm.

Clinical trials

Registered studies of Respiral (respiflutide inhalation powder).

Phase IIICompletedBPC-RS-302

BREATHE-12: Respiral 250 mcg vs placebo in moderate asthma

Primary endpoint: Change in trough FEV1 at week 12
Enrolment: 2,380 · Sites: Australia, United Kingdom, Brazil, South Korea

Phase IIActive, not recruitingBPC-RS-205

BREATHE-TEEN: Growth velocity in adolescents

Primary endpoint: Linear growth velocity over 52 weeks
Enrolment: 410 · Sites: Australia, New Zealand